Targeting the translation machinery in cancer (Q38368049)

2 September 2017

1 reference

title

Targeting the translation machinery in cancer (English)

1 reference

2 September 2017

4

Nahum Sonenberg

1 reference

2 September 2017

Laura Hulea

3

0 references

Nathaniel Robichaud

object named as

Nathaniel Robichaud

2

0 references

Ivan Topisirovic

object named as

Ivan Topisirovic

6

0 references

author name string

Mamatha Bhat

1

1 reference

PubMed ID

25743081

2 September 2017

Jerry Pelletier

5

1 reference

PubMed ID

25743081

2 September 2017

language of work or name

1 reference

6 March 2015

1 reference

Nature Reviews Drug Discovery

2 September 2017

1 reference

2 September 2017

14

1 reference

2 September 2017

4

1 reference

2 September 2017

261-278

1 reference

https://scigraph.springernature.com/pub.10.1038/nrd4505

2 September 2017

0 references

cites work

Regulation of translation initiation in eukaryotes: mechanisms and biological targets

1 reference

A hierarchy of ATP-consuming processes in mammalian cells

31 March 2020

1 reference

Cellular energy utilization and molecular origin of standard metabolic rate in mammals

31 March 2020

1 reference

Changes in RNA in relation to growth of the fibroblast. IV. Alterations in theproduction and processing of mRNA and rRNA in resting and growing cells

31 March 2020

1 reference

Translational control of the innate immune response through IRF-7

31 March 2020

1 reference

Eukaryotic translation initiation factor 4E induced progression of primary human mammary epithelial cells along the cancer pathway is associated with targeted translational deregulation of oncogenic drivers and inhibitors

31 March 2020

1 reference

Apoptosis resistance downstream of eIF4E: posttranscriptional activation of an anti-apoptotic transcript carrying a consensus hairpin structure.

31 March 2020

1 reference

Translational control of programmed cell death: eukaryotic translation initiation factor 4E blocks apoptosis in growth-factor-restricted fibroblasts with physiologically expressed or deregulated Myc.

31 March 2020

1 reference

Translational regulation of vascular permeability factor by eukaryotic initiation factor 4E: implications for tumor angiogenesis

31 March 2020

1 reference

Tinkering with translation: protein synthesis in virus-infected cells

31 March 2020

1 reference

mRNA translation and energy metabolism in cancer: the role of the MAPK and mTORC1 pathways

31 March 2020

1 reference

Hallmarks of Cancer: The Next Generation

31 March 2020

1 reference

31 March 2020

The Hallmarks of Cancer

1 reference

Post-transcriptional regulatory networks in immunity.

31 March 2020

1 reference

Cap-dependent translational inhibition establishes two opposing morphogen gradients in Drosophila embryos

31 March 2020

1 reference

A requirement for local protein synthesis in neurotrophin-induced hippocampal synaptic plasticity

31 March 2020

1 reference

Global quantification of mammalian gene expression control

31 March 2020

1 reference

Comparative analysis of proteome and transcriptome variation in mouse

31 March 2020

1 reference

Insights into the regulation of protein abundance from proteomic and transcriptomic analyses

31 March 2020

1 reference

Protein synthesis rate is the predominant regulator of protein expression during differentiation

31 March 2020

1 reference

Translation factors and ribosomal proteins control tumor onset and progression: how?

31 March 2020

1 reference

Growth control and ribosomopathies.

31 March 2020

1 reference

Translational control in cancer etiology

31 March 2020

1 reference

Ribosomal dysfunction and inherited marrow failure

31 March 2020

1 reference

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

31 March 2020

1 reference

Translational control in cancer.

31 March 2020

1 reference

Eukaryotic translation initiation factor 4E regulates expression of cyclin D1 at transcriptional and post-transcriptional levels

31 March 2020

1 reference

Protein and nucleotide biosynthesis are coupled by a single rate-limiting enzyme, PRPS2, to drive cancer

31 March 2020

1 reference

eIF-4E expression and its role in malignancies and metastases.

31 March 2020

1 reference

The requirement for eukaryotic initiation factor 4A (elF4A) in translation is in direct proportion to the degree of mRNA 5' secondary structure.

31 March 2020

1 reference

Human eIF4E promotes mRNA restructuring by stimulating eIF4A helicase activity

31 March 2020

1 reference

eIF4GI links nutrient sensing by mTOR to cell proliferation and inhibition of autophagy

31 March 2020

1 reference

RNA G-quadruplexes cause eIF4A-dependent oncogene translation in cancer

31 March 2020

1 reference

mTOR signaling in growth control and disease

31 March 2020

1 reference

Talks about TORCs: recent advancesin target of rapamycin signalling. On mTOR nomenclature

31 March 2020

1 reference

A comprehensive map of the mTOR signaling network

31 March 2020

1 reference

mTOR complex 2 signaling and functions

31 March 2020

1 reference

Regulation of mRNA translation by signaling pathways

31 March 2020

1 reference

Insulin-dependent stimulation of protein synthesis by phosphorylation of a regulator of 5'-cap function

31 March 2020

1 reference

Rapamycin blocks the phosphorylation of 4E-BP1 and inhibits cap-dependent initiation of translation

31 March 2020

1 reference

Phosphorylation of the translational repressor PHAS-I by the mammalian target of rapamycin

31 March 2020

1 reference

Regulation of 4E-BP1 phosphorylation: a novel two-step mechanism

31 March 2020

1 reference

4E-BP1, a repressor of mRNA translation, is phosphorylated and inactivated by the Akt(PKB) signaling pathway

31 March 2020

1 reference

4E-BP1 phosphorylation is mediated by the FRAP-p70s6k pathway and is independent of mitogen-activated protein kinase

31 March 2020

1 reference

RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1

31 March 2020

1 reference

Phosphorylated Mnk1 and eIF4E are associated with lymph node metastasis and poor prognosis of nasopharyngeal carcinoma

31 March 2020

1 reference

Regulation of eIF-4E BP1 phosphorylation by mTOR.

31 March 2020

1 reference

Control of p70 s6 kinase by kinase activity of FRAP in vivo

31 March 2020

1 reference

Amino acid sufficiency and mTOR regulate p70 S6 kinase and eIF-4E BP1 through a common effector mechanism

31 March 2020

1 reference

Molecular structure of a major insulin/mitogen-activated 70-kDa S6 protein kinase

31 March 2020

1 reference

Phosphorylation of eucaryotic translation initiation factor 4B Ser422 is modulated by S6 kinases

31 March 2020

1 reference

S6K1- and betaTRCP-mediated degradation of PDCD4 promotes protein translation and cell growth

31 March 2020

1 reference

The transformation suppressor Pdcd4 is a novel eukaryotic translation initiation factor 4A binding protein that inhibits translation

31 March 2020

1 reference

Serum-stimulated, rapamycin-sensitive phosphorylation sites in the eukaryotic translation initiation factor 4GI.

31 March 2020

1 reference

Regulation of elongation factor 2 kinase by p90(RSK1) and p70 S6 kinase.

31 March 2020

1 reference

mTOR-dependent activation of the transcription factor TIF-IA links rRNA synthesis to nutrient availability

31 March 2020

1 reference

mTORC1 directly phosphorylates and regulates human MAF1.

31 March 2020

1 reference

Ribosomal protein S6 kinase from TOP mRNAs to cell size

31 March 2020

1 reference

Genome-wide analysis in vivo of translation with nucleotide resolution using ribosome profiling

31 March 2020

1 reference

A unifying model for mTORC1-mediated regulation of mRNA translation.

31 March 2020

1 reference

The translational landscape of mTOR signalling steers cancer initiation and metastasis

31 March 2020

1 reference

Toward a genome-wide landscape of translational control

31 March 2020

1 reference

Distinct perturbation of the translatome by the antidiabetic drug metformin

31 March 2020

1 reference

mTORC1 controls mitochondrial activity and biogenesis through 4E-BP-dependent translational regulation.

31 March 2020

1 reference

Oxygen sufficiency controls TOP mRNA translation via the TSC-Rheb-mTOR pathway in a 4E-BP-independent manner.

31 March 2020

1 reference

Proteomic analysis of cap-dependent translation identifies LARP1 as a key regulator of 5'TOP mRNA translation

31 March 2020

1 reference

The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling.

31 March 2020

1 reference

LARP1 specifically recognizes the 3' terminus of poly(A) mRNA

31 March 2020

1 reference

Phosphorylation of the cap-binding protein eukaryotic translation initiation factor 4E by protein kinase Mnk1 in vivo

31 March 2020

1 reference

Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases

31 March 2020

1 reference

The Mnks: MAP kinase-interacting kinases (MAP kinase signal-integrating kinases).

31 March 2020

1 reference

Mitogen-activated protein kinases activate the serine/threonine kinases Mnk1 and Mnk2

31 March 2020

1 reference

MNK1, a new MAP kinase-activated protein kinase, isolated by a novel expression screening method for identifying protein kinase substrates

31 March 2020

1 reference

The mitogen-activated protein kinase signal-integrating kinase Mnk2 is a eukaryotic initiation factor 4E kinase with high levels of basal activity in mammalian cells

31 March 2020

1 reference

Human eukaryotic translation initiation factor 4G (eIF4G) recruits mnk1 to phosphorylate eIF4E

31 March 2020

1 reference

Coupling 40S ribosome recruitment to modification of a cap-binding initiation factor by eIF3 subunit e.

31 March 2020

1 reference

Dissecting eIF4E action in tumorigenesis

31 March 2020

1 reference

eIF4E phosphorylation promotes tumorigenesis and is associated with prostate cancer progression

31 March 2020

1 reference

Mnk Kinases in Cytokine Signaling and Regulation of Cytokine Responses

31 March 2020

1 reference

Increased expression of eukaryotic translation initiation factors eIF-4E and eIF-2 alpha in response to growth induction by c-myc

31 March 2020

1 reference

Up-regulation of translation eukaryotic initiation factor 4E in nucleophosmin 1 haploinsufficient cells results in changes in CCAAT enhancer-binding protein α activity: implications in myelodysplastic syndrome and acute myeloid leukemia.

31 March 2020

1 reference

The eukaryotic translation initiation factor eIF4E is a direct transcriptional target of NF-κB and is aberrantly regulated in acute myeloid leukemia

31 March 2020

1 reference

Hypoxia-inducible factor-1α (HIF-1α) promotes cap-dependent translation of selective mRNAs through up-regulating initiation factor eIF4E1 in breast cancer cells under hypoxia conditions

31 March 2020

1 reference

Stability of eukaryotic translation initiation factor 4E mRNA is regulated by HuR, and this activity is dysregulated in cancer.

31 March 2020

1 reference

An essential E box in the promoter of the gene encoding the mRNA cap-binding protein (eukaryotic initiation factor 4E) is a target for activation by c-myc

31 March 2020

1 reference

c-Myc and eIF4F are components of a feedforward loop that links transcription and translation

31 March 2020

1 reference

MYC as a regulator of ribosome biogenesis and protein synthesis

31 March 2020

1 reference

Malignant transformation by a eukaryotic initiation factor subunit that binds to mRNA 5' cap

31 March 2020

1 reference

Decreasing the level of translation initiation factor 4E with antisense RNA causes reversal of ras-mediated transformation and tumorigenesis of cloned rat embryo fibroblasts.

31 March 2020

1 reference

Expression of antisense RNA against initiation factor eIF-4E mRNA in HeLa cells results in lengthened cell division times, diminished translation rates, and reduced levels of both eIF-4E and the p220 component of eIF-4F.

31 March 2020

2 references

31 March 2020

12 December 2020

Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy

1 reference

The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis

31 March 2020

1 reference

eIF4E--from translation to transformation

31 March 2020

1 reference

Progression of eIF4e gene amplification and overexpression in benign and malignant tumors of the head and neck.

31 March 2020

1 reference

eIF4E activity is regulated at multiple levels

31 March 2020

1 reference

Genetic dissection of the oncogenic mTOR pathway reveals druggable addiction to translational control via 4EBP-eIF4E

31 March 2020

1 reference

Activation of translation complex eIF4F is essential for the genesis and maintenance of the malignant phenotype in human mammary epithelial cells

31 March 2020

1 reference

Activated eIF4E-binding Protein Slows G1 Progression and Blocks Transformation by c-myc without Inhibiting Cell Growth

31 March 2020

1 reference

mTORC1-mediated cell proliferation, but not cell growth, controlled by the 4E-BPs

31 March 2020

1 reference

p53-dependent translational control of senescence and transformation via 4E-BPs.

31 March 2020

1 reference

Anti-oncogenic potential of the eIF4E-binding proteins

31 March 2020

1 reference

mTOR: from growth signal integration to cancer, diabetes and ageing

31 March 2020

1 reference

Phosphorylation of the eukaryotic translation initiation factor eIF4E contributes to its transformation and mRNA transport activities

31 March 2020

1 reference

Phosphorylation of eIF4E promotes EMT and metastasis via translational control of SNAIL and MMP-3.

31 March 2020

1 reference

Upregulation of protein synthesis initiation factor eIF-4E is an early event during colon carcinogenesis

31 March 2020

1 reference

Elevated expression of eIF4E and FGF-2 isoforms during vascularization of breast carcinomas

31 March 2020

1 reference

Expression of eukaryotic initiation factor 4E in gastric adenocarcinoma and its association with clinical outcome.

31 March 2020

1 reference

Analysis of surgical margins with the molecular marker eIF4E: a prognostic factor in patients with head and neck cancer

31 March 2020

1 reference

Defining the role of mTOR in cancer

31 March 2020

1 reference

Targeting the mitogen-activated protein kinase cascade to treat cancer

31 March 2020

1 reference

4E-binding protein 1: a key molecular "funnel factor" in human cancer with clinical implications

31 March 2020

1 reference

eIF4E activation is commonly elevated in advanced human prostate cancers and significantly related to reduced patient survival.

31 March 2020

1 reference

Frequent overexpression of the genes FXR1, CLAPM1 and EIF4G located on amplicon 3q26-27 in squamous cell carcinoma of the lung

31 March 2020

1 reference

Essential role for eIF4GI overexpression in the pathogenesis of inflammatory breast cancer.

31 March 2020

1 reference

Decreased expression of EIF4A1 after preoperative brachytherapy predicts better tumor-specific survival in cervical cancer.

31 March 2020

1 reference

Over-expression of eukaryotic translation initiation factor 4 gamma 1 correlates with tumor progression and poor prognosis in nasopharyngeal carcinoma

31 March 2020

1 reference

Aberrations in translational regulation are associated with poor prognosis in hormone receptor-positive breast cancer

31 March 2020

1 reference

Loss of PDCD4 expression in human lung cancer correlates with tumour progression and prognosis

31 March 2020

1 reference

Loss of programmed cell death 4 expression marks adenoma-carcinoma transition, correlates inversely with phosphorylated protein kinase B, and is an independent prognostic factor in resected colorectal cancer

31 March 2020

1 reference

PDCD4 gene silencing in gliomas is associated with 5'CpG island methylation and unfavourable prognosis

31 March 2020

1 reference

Down-regulation of PDCD4 expression is an independent predictor of poor prognosis in human renal cell carcinoma patients

31 March 2020

1 reference

The intra-tumor heterogeneity of cell signaling factors in breast cancer: p4E-BP1 and peIF4E are diffusely expressed and are real potential targets.

31 March 2020

1 reference

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer

31 March 2020

1 reference

eIF4E/4E-BP ratio predicts the efficacy of mTOR targeted therapies

31 March 2020

1 reference

Resistance to mTOR kinase inhibitors in lymphoma cells lacking 4EBP1

31 March 2020

1 reference

eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies

31 March 2020

1 reference

PI3K and cancer: lessons, challenges and opportunities

31 March 2020

1 reference

Emerging therapeutics targeting mRNA translation

31 March 2020

1 reference

Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle

31 March 2020

1 reference

Targets for Cell Cycle Arrest by the Immunosuppressant Rapamycin in Yeast

31 March 2020

1 reference

A mammalian protein targeted by G1-arresting rapamycin-receptor complex

31 March 2020

1 reference

Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action

31 March 2020

1 reference

mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery

31 March 2020

1 reference

mTOR kinase structure, mechanism and regulation

31 March 2020

1 reference

Dissociation of raptor from mTOR is a mechanism of rapamycin-induced inhibition of mTOR function

31 March 2020

1 reference

Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton

31 March 2020

1 reference

Structure of the human mTOR complex I and its implications for rapamycin inhibition.

31 March 2020

1 reference

mTORC1 phosphorylation sites encode their sensitivity to starvation and rapamycin

31 March 2020

1 reference

Rapamycin resistance: mTORC1 substrates hold some of the answers

31 March 2020

1 reference

Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB

31 March 2020

1 reference

Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity

31 March 2020

1 reference

Targeting TOR dependence in cancer

31 March 2020

1 reference

Rapamycin passes the torch: a new generation of mTOR inhibitors

31 March 2020

1 reference

Restraining PI3K: mTOR signalling goes back to the membrane.

31 March 2020

1 reference

Not all substrates are treated equally: implications for mTOR, rapamycin-resistance and cancer therapy

31 March 2020

1 reference

Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling

31 March 2020

1 reference

A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma

31 March 2020

1 reference

An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1

31 March 2020

1 reference

Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2

31 March 2020

1 reference

Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR)

31 March 2020

1 reference

mTOR.RICTOR is the Ser473 kinase for Akt/protein kinase B in 3T3-L1 adipocytes

31 March 2020

1 reference

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex

31 March 2020

1 reference

Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation

31 March 2020

1 reference

AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity

31 March 2020

1 reference

Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor

31 March 2020

1 reference

Efficacy of the investigational mTOR kinase inhibitor MLN0128/INK128 in models of B-cell acute lymphoblastic leukemia

31 March 2020

1 reference

Response to mTOR inhibition: activity of eIF4E predicts sensitivity in cell lines and acquired changes in eIF4E regulation in breast cancer

31 March 2020

1 reference

PI3K-targeted therapy can be evaded by gene amplification along the MYC-eukaryotic translation initiation factor 4E (eIF4E) axis

31 March 2020

1 reference

Adaptation to mTOR kinase inhibitors by amplification of eIF4E to maintain cap-dependent translation.

31 March 2020

1 reference

Pancreatic tumours escape from translational control through 4E-BP1 loss.

31 March 2020

1 reference

mTOR inhibitor efficacy is determined by the eIF4E/4E-BP ratio

31 March 2020

1 reference

Combined analysis of eIF4E and 4E-binding protein expression predicts breast cancer survival and estimates eIF4E activity

31 March 2020

1 reference

Inhibition of PI3K/mTOR leads to adaptive resistance in matrix-attached cancer cells

31 March 2020

1 reference

Diabetes mellitus and risk of colorectal cancer: a meta-analysis

31 March 2020

1 reference

Diabetes mellitus and risk of breast cancer: a meta-analysis

31 March 2020

1 reference

Potential applications for biguanides in oncology

31 March 2020

1 reference

Investigating metformin for cancer prevention and treatment: the end of the beginning

31 March 2020

1 reference

Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells

31 March 2020

1 reference

Therapeutic inhibition of MAP kinase interacting kinase blocks eukaryotic initiation factor 4E phosphorylation and suppresses outgrowth of experimental lung metastases

31 March 2020

1 reference

Phosphorylation of eIF-4E on Ser 209 in response to mitogenic and inflammatory stimuli is faithfully detected by specific antibodies

31 March 2020

1 reference

Negative regulation of protein translation by mitogen-activated protein kinase-interacting kinases 1 and 2

31 March 2020

1 reference

The selectivity of protein kinase inhibitors: a further update

31 March 2020

1 reference

MAP kinase-interacting kinases--emerging targets against cancer

31 March 2020

1 reference

Discovery of 5-(2-(phenylamino)pyrimidin-4-yl)thiazol-2(3H)-one derivatives as potent Mnk2 inhibitors: synthesis, SAR analysis and biological evaluation

31 March 2020

1 reference

Rational design of resorcylic acid lactone analogues as covalent MNK1/2 kinase inhibitors by tuning the reactivity of an enamide Michael acceptor

31 March 2020

1 reference

First MNKs degrading agents block phosphorylation of eIF4E, induce apoptosis, inhibit cell growth, migration and invasion in triple negative and Her2-overexpressing breast cancer cell lines

31 March 2020

1 reference

Gemcitabine triggers a pro-survival response in pancreatic cancer cells through activation of the MNK2/eIF4E pathway.

31 March 2020

1 reference

MKNK1 is a YB-1 target gene responsible for imparting trastuzumab resistance and can be blocked by RSK inhibition

31 March 2020

1 reference

Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition.

31 March 2020

1 reference

Intrinsic and acquired resistance to MEK1/2 inhibitors in cancer

31 March 2020

1 reference

Antisense RNA to eIF4E suppresses oncogenic properties of a head and neck squamous cell carcinoma cell line.

31 March 2020

1 reference

Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity

31 March 2020

1 reference

Targeting synthetic lethal interactions between Myc and the eIF4F complex impedes tumorigenesis

31 March 2020

1 reference

Pronucleotides: toward the in vivo delivery of antiviral and anticancer nucleotides

31 March 2020

1 reference

Nontoxic chemical interdiction of the epithelial-to-mesenchymal transition by targeting cap-dependent translation

31 March 2020

1 reference

Treatment of breast and lung cancer cells with a N-7 benzyl guanosine monophosphate tryptamine phosphoramidate pronucleotide (4Ei-1) results in chemosensitization to gemcitabine and induced eIF4E proteasomal degradation.

31 March 2020

1 reference

Cap-dependent translation initiation factor eIF4E: an emerging anticancer drug target

31 March 2020

1 reference

Structure-guided design, synthesis, and evaluation of guanine-derived inhibitors of the eIF4E mRNA-cap interaction

31 March 2020

1 reference

Virus-like particle-mediated intracellular delivery of mRNA cap analog with in vivo activity against hepatocellular carcinoma

31 March 2020

1 reference

Ribavirin suppresses eIF4E-mediated oncogenic transformation by physical mimicry of the 7-methyl guanosine mRNA cap

31 March 2020

1 reference

Ribavirin is not a functional mimic of the 7-methyl guanosine mRNA cap.

31 March 2020

1 reference

The antiviral drug ribavirin does not mimic the 7-methylguanosine moiety of the mRNA cap structure in vitro

31 March 2020

1 reference

Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): a proof-of-principle clinical trial with ribavirin.

31 March 2020

1 reference

Targeting translation dependence in cancer

31 March 2020

1 reference

Cap-dependent translation initiation in eukaryotes is regulated by a molecular mimic of eIF4G

31 March 2020

1 reference

Structure of translation factor eIF4E bound to m7GDP and interaction with 4E-binding protein

31 March 2020

1 reference

The interaction of eIF4E with 4E-BP1 is an induced fit to a completely disordered protein

31 March 2020

1 reference

Requirement of RNA binding of mammalian eukaryotic translation initiation factor 4GI (eIF4GI) for efficient interaction of eIF4E with the mRNA cap.

31 March 2020

1 reference

Dynamic recognition of the mRNA cap by Saccharomyces cerevisiae eIF4E.

31 March 2020

1 reference

The translation initiation factor eIF-4E binds to a common motif shared by the translation factor eIF-4 gamma and the translational repressors 4E-binding proteins

31 March 2020

1 reference

A novel inhibitor of cap-dependent translation initiation in yeast: p20 competes with eIF4G for binding to eIF4E.

31 March 2020

1 reference

Small-molecule inhibition of the interaction between the translation initiation factors eIF4E and eIF4G

31 March 2020

1 reference

Blocking eIF4E-eIF4G interaction as a strategy to impair coronavirus replication.

31 March 2020

1 reference

Structure of the eukaryotic translation initiation factor eIF4E in complex with 4EGI-1 reveals an allosteric mechanism for dissociating eIF4G

31 March 2020

1 reference

Translation of viral mRNAs that do not require eIF4E is blocked by the inhibitor 4EGI-1.

31 March 2020

1 reference

Cap-translation inhibitor, 4EGI-1, restores sensitivity to ABT-737 apoptosis through cap-dependent and -independent mechanisms in chronic lymphocytic leukemia

31 March 2020

1 reference

Inhibition of ovarian cancer growth by a tumor-targeting peptide that binds eukaryotic translation initiation factor 4E.

31 March 2020

1 reference

Functional characterization of IRESes by an inhibitor of the RNA helicase eIF4A.

31 March 2020

1 reference

Stimulation of mammalian translation initiation factor eIF4A activity by a small molecule inhibitor of eukaryotic translation

31 March 2020

1 reference

Inhibition of eukaryotic translation initiation by the marine natural product pateamine A.

31 March 2020

1 reference

Second-generation derivatives of the eukaryotic translation initiation inhibitor pateamine A targeting eIF4A as potential anticancer agents

31 March 2020

1 reference

Potent in vitro and in vivo anticancer activities of des-methyl, des-amino pateamine A, a synthetic analogue of marine natural product pateamine A

31 March 2020

1 reference

Effects of hippuristanol, an inhibitor of eIF4A, on adult T-cell leukemia

31 March 2020

1 reference

Modifying chemotherapy response by targeted inhibition of eukaryotic initiation factor 4A.

31 March 2020

1 reference

Antitumor activity and mechanism of action of the cyclopenta[b]benzofuran, silvestrol

31 March 2020

1 reference

Evidence for a functionally relevant rocaglamide binding site on the eIF4A-RNA complex

31 March 2020

1 reference

Synthetic silvestrol analogues as potent and selective protein synthesis inhibitors

31 March 2020

1 reference

Transcriptome-wide characterization of the eIF4A signature highlights plasticity in translation regulation

31 March 2020

1 reference

Formation of the eIF4F translation-initiation complex determines sensitivity to anticancer drugs targeting the EGFR and HER2 receptors.

31 March 2020

1 reference

Resistance to the translation initiation inhibitor silvestrol is mediated by ABCB1/P-glycoprotein overexpression in acute lymphoblastic leukemia cells

31 March 2020

1 reference

Simplified silvestrol analogues with potent cytotoxic activity.

31 March 2020

1 reference

The scanning mechanism of eukaryotic translation initiation

31 March 2020

1 reference

Tight binding of the phosphorylated alpha subunit of initiation factor 2 (eIF2alpha) to the regulatory subunits of guanine nucleotide exchange factor eIF2B is required for inhibition of translation initiation

31 March 2020

1 reference

Phosphorylation inhibits guanine nucleotide exchange on eukaryotic initiation factor 2.

31 March 2020

1 reference

Phosphorylation of initiation factor 2 alpha by protein kinase GCN2 mediates gene-specific translational control of GCN4 in yeast

31 March 2020

1 reference

Regulated translation initiation controls stress-induced gene expression in mammalian cells

31 March 2020

1 reference

Multiple upstream AUG codons mediate translational control of GCN4.

31 March 2020

1 reference

Reinitiation involving upstream ORFs regulates ATF4 mRNA translation in mammalian cells

31 March 2020

1 reference

Gene-specific translational control of the yeast GCN4 gene by phosphorylation of eukaryotic initiation factor 2.

31 March 2020

1 reference

Control of oncogenesis by eIF2α phosphorylation: implications in PTEN and PI3K-Akt signaling and tumor treatment

31 March 2020

1 reference

ER stress-regulated translation increases tolerance to extreme hypoxia and promotes tumor growth

31 March 2020

1 reference

Abrogation of translation initiation factor eIF-2 phosphorylation causes malignant transformation of NIH 3T3 cells.

31 March 2020

1 reference

The protein kinase PKR: a molecular clock that sequentially activates survival and death programs

31 March 2020

1 reference

Chemical genetics identify eIF2α kinase heme-regulated inhibitor as an anticancer target

31 March 2020

1 reference

In vitro inhibition of translation initiation by N,N'-diarylureas--potential anti-cancer agents

31 March 2020

1 reference

A selective inhibitor of eIF2alpha dephosphorylation protects cells from ER stress

31 March 2020

1 reference

Inhibition of eIF2alpha dephosphorylation maximizes bortezomib efficiency and eliminates quiescent multiple myeloma cells surviving proteasome inhibitor therapy

31 March 2020

1 reference

Integrated endoplasmic reticulum stress responses in cancer

31 March 2020

1 reference

Targeting the unfolded protein response in disease.

31 March 2020

1 reference

Selective inhibition of a regulatory subunit of protein phosphatase 1 restores proteostasis

31 March 2020

1 reference

Attenuation of malignant phenotypes of breast cancer cells through eIF2α-mediated downregulation of Rac1 signaling.

31 March 2020

1 reference

Initiation of Protein Synthesis by Hepatitis C Virus Is Refractory to Reduced eIF2 · GTP · Met-tRNAiMet Ternary Complex Availability

31 March 2020

1 reference

Asparaginase-induced derangements of glutamine metabolism: the pathogenetic basis for some drug-related side-effects.

31 March 2020

1 reference

Sequential administration of methotrexate and asparaginase in relapsed or refractory pediatric acute myeloid leukemia

31 March 2020

1 reference

GCN2 protein kinase is required to activate amino acid deprivation responses in mice treated with the anti-cancer agent L-asparaginase.

31 March 2020

1 reference

Inhibition of Protein Synthesis in Intact HeLa Cells

31 March 2020

1 reference

RNA polymerases I and III, growth control and cancer

31 March 2020

1 reference

Targeting RNA polymerase I with an oral small molecule CX-5461 inhibits ribosomal RNA synthesis and solid tumor growth.

31 March 2020

1 reference

Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53

31 March 2020

1 reference

Inhibition of eukaryotic translation initiation factor 5A (eIF5A) hypusination impairs melanoma growth

31 March 2020

1 reference

Functional significance of eIF5A and its hypusine modification in eukaryotes

31 March 2020

1 reference

Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework

31 March 2020

1 reference

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

31 March 2020

1 reference

Everolimus for advanced pancreatic neuroendocrine tumors.

31 March 2020

1 reference

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer

31 March 2020

1 reference

Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis

31 March 2020

1 reference

Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis

31 March 2020

1 reference

Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma

31 March 2020

1 reference

Mechanisms of Disease: survival benefit of temsirolimus validates a role for mTOR in the management of advanced RCC.

31 March 2020

1 reference

Everolimus long-term safety and efficacy in subependymal giant cell astrocytoma

31 March 2020

1 reference

Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy

31 March 2020

1 reference

Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth

31 March 2020

1 reference

Metformin prevents tobacco carcinogen--induced lung tumorigenesis

31 March 2020

1 reference

Metformin attenuates the stimulatory effect of a high-energy diet on in vivo LLC1 carcinoma growth

31 March 2020

1 reference

Prevention of pancreatic cancer induction in hamsters by metformin

31 March 2020

1 reference

A phase 1 dose escalation, pharmacokinetic, and pharmacodynamic evaluation of eIF-4E antisense oligonucleotide LY2275796 in patients with advanced cancer

31 March 2020

1 reference

c-Myc and eIF4F constitute a feedforward loop that regulates cell growth: implications for anticancer therapy

31 March 2020

1 reference

RNA polymerases I and III, non-coding RNAs and cancer

31 March 2020

1 reference

Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases.

31 March 2020

1 reference

Metformin and cancer: mounting evidence against an association.

31 March 2020

1 reference

Regulated phosphorylation and low abundance of HeLa cell initiation factor eIF-4F suggest a role in translational control. Heat shock effects on eIF-4F

31 March 2020

1 reference

12 December 2020

Harringtonine, an inhibitor of initiation of protein biosynthesis

1 reference

12 December 2020

Translational control of ornithine aminotransferase. Modulation by initiation factor eIF-4E.

1 reference

12 December 2020

Purification of the eukaryotic initiation factor 2-eukaryotic initiation factor 2B complex and characterization of its guanine nucleotide exchange activity during protein synthesis initiation

1 reference

12 December 2020

Expression and prognostic significance of PDCD4 in human epithelial ovarian carcinoma.

1 reference

12 December 2020

Immunological detection of the messenger RNA cap-binding protein

1 reference

12 December 2020

Dominant negative mutants of mammalian translation initiation factor eIF-4A define a critical role for eIF-4F in cap-dependent and cap-independent initiation of translation

1 reference

12 December 2020

Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase

1 reference

12 December 2020

Antiproliferative effects of inhibitors of deoxyhypusine synthase. Inhibition of growth of Chinese hamster ovary cells by guanyl diamines.

1 reference

12 December 2020

Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer

1 reference

12 December 2020

L-asparaginase therapy for leukemia and other malignant neoplasms. Remission in human leukemia

1 reference

12 December 2020

mRNAs containing extensive secondary structure in their 5' non-coding region translate efficiently in cells overexpressing initiation factor eIF-4E

1 reference

12 December 2020

Tumor suppression by small molecule inhibitors of translation initiation.

1 reference

12 December 2020

Therapeutic suppression of translation initiation modulates chemosensitivity in a mouse lymphoma model

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRD4505

1 reference

2 September 2017

1 reference

PubMed ID

25743081